PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470)
Affiliations: LOUISIANA STATE UNIV,MED CTR,DEPT MED,CTR EXCELLENCE CANC RES TREATMENT & EDUC,SHREVEPORT,LA 71130.
- Published online on: November 1, 1995 https://doi.org/10.3892/or.2.6.1101
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
A 61-year-old man with progressive prostate cancer after initial hormonal therapy was treated with TNP-470, an experimental agent with potent antiangiogenesis properties. During the period of TNP-470 treatment, the concentration of serum prostate-specific antigen (PSA) rapidly increased from 28.4 to 89.9 ng/ml. After termination of TNP-470 therapy, the concentration of PSA decreased from 89.9 to 10.3 ng/ml. This pattern of PSA change was previously unanticipated and may eventually provide additional insight into the pharmacological actions of TNP-470.